MOLECULAR INFORMATION
Molecular information
- Type
- ERR (estrogen-related receptor) pan-agonist · investigational exercise-mimetic
SLU-PP-332 is a research-stage ERR agonist, sold grey-market alongside peptides despite being a small molecule.
Claims vs evidence
- Exercise-mimetic activity — rodent treadmill / metabolic-cage data
- Fat-loss / endurance benefit in humans — extrapolated, no trial
- Body-composition change — no human RCT
Why we grade it D
Promising preclinical biology, zero human evidence. The “exercise in a pill” framing is exactly the kind of claim that needs clinical demonstration before it can be sold; vendors selling SLU-PP-332 with performance claims are running ahead of the data.
Frequently asked questions
- What is SLU-PP-332?
- A small-molecule (technically not a peptide) pan-agonist of the estrogen-related receptors (ERRα/β/γ), developed at Saint Louis University. Promoted as an "exercise-mimetic" because ERR activation upregulates mitochondrial biogenesis and oxidative metabolism.
- Is SLU-PP-332 a peptide?
- No — it is a synthetic small molecule. It is listed in peptidepedia because grey-market peptide vendors stock it alongside genuine peptides, and readers expect coverage.
- Is it authorised?
- No — preclinical research compound. Mouse studies show enhanced exercise capacity and metabolic adaptation; no human trials are registered. Grey-market sales make claims well beyond the data.